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ABSTRACT
Treatment for extensive-stage small cell lung cancer (ES SCLC) or extrapulmonary small cell carcinoma (EPSC) is
typically palliative. We set out to determine progression-free survival (PFS) and overall long-term survival of ES
SCLC and EPSC patients, physiologically aged ≤60 years, responding to first-line chemotherapy followed by high-
dose combination alkylating agents with hematologic stem cell support. Patients in first-line chemotherapy
response underwent stem cell collection (marrow, peripheral blood progenitor cells, or both) followed by high-
dose therapy with 1 of 2 regimens: CBP (cyclophosphamide, cisplatin, and carmustine) or ICE (ifosfamide, carbo-
platin, and etoposide) with or without etanidazole. Involved-field radiotherapy was given to selected patients with
oligometastatic disease distributed in sites allowing for reasonable radiation ports, and prophylactic cranial radio-
therapy was given upon recovery to patients in complete response (CR) or near-CR. A total of 36 patients were
treated. Of 29 patients with ES SCLC, 6 (21%) had achieved CR, 18 near-CR, and 5 partial response prior to high-
dose therapy. Of 7 patients with EPSC, 3 (43%) had achieved CR, 3 had achieved near-CR, and 1 had progression
of disease prior to high-dose therapy. Thirteen ES SCLC patients received high-dose CBP. Of the remaining
23 patients with SCLC or EPSC, 17 were treated with ICE and 6 with ICE plus etanidazole, a hypoxic cell sensi-
tizer. Treatment-related mortality was 11% (4 of 36 patients). For all patients, the median event-free survival
(EFS) was 5 months. The 2- and 5-year survivals after intensification were 12% (95% confidence interval [CI], 5%-
31%) and 9% (95% CI, 3%-27%), respectively. Of the 30 patients in or near CR prior to high-dose therapy,
5 remain continuously progression-free (2 ES SCLC, 3 EPSC) for a median of 55 months (range, 1-96 months)
after high-dose therapy. By multivariate analysis, factors associated with more favorable EFS were the use of a
more aggressive induction regimen (ICE), and the EPSC histology. These factors were also associated with more
favorable overall survival. Other factors associated with more favorable overall survival were the use of short induc-
tion therapy (≤4 cycles) and younger age (<50 years). Except for high-dose ICE with etanidazole, the use of high-
dose systemic therapy in ES SCLC and EPSC was associated with low treatment-related morbidity and mortality
over the past 5 years. Late complications were infrequent, and most patients returned to full-time work and activ-
ity, barring disease recurrence. Nonetheless, few patients with ES SCLC have progression-free long-term survival.
We conclude that high-dose therapy is not indicated as an approach for ES SCLC, except as part of an investigative
trial. Conversely, 3 of the 7 patients with EPSC remain relapse-free (range, 1-96 months), warranting further
phase II evaluation of this approach in this population.
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INTRODUCTION: RATIONALE FOR DOSE-INTENSIVE
THERAPY IN SMALL CELL LUNG CANCERS
Tobacco-related respiratory cancers are the leading pre-
ventable cause of death from cancer in both men and women
[1]. Approximately 30,000 new cases of small cell lung can-
cers (SCLC) arise each year in the United States, of which
two thirds are metastatic (extensive-stage [ES] SCLC).
Extrapulmonary small cell carcinomas (EPSC) arise in
numerous organs, typically from respiratory, gastrointestinal,
or gynecologic tracts, and are relatively rare. They are
included in this report because their biologic behavior and
response to therapy are quite similar to that of ES SCLC [2].
Treatment is palliative and usually consists of 4 to 6 cycles of
combination chemotherapy such as etoposide and platinum
(EP) or carboplatin (CbE) [3]. Overall response rates are
about 60% (13%-25% complete responses [CR]), but practi-
cally all patients will relapse within months. Expected
median survival is 10 to 14 months from initiation of therapy.
Only about 5% of patients remain alive by 2 years, and fewer
than 2% survive 5 years [4].
The utility of dose or dose intensity of chemotherapy
to enhance response and survival remains controversial.
Standard combination chemotherapy is superior to low-
dose treatment; however, no clear benefit has been docu-
mented with modest or high dose escalation [5-12]. In the
only randomized trial comparing transplantation to con-
ventional therapy, Humblet et al. [13] treated 101 SCLC
patients with 5 cycles of chemotherapy but without thoracic
radiotherapy. Forty-five (13 ES SCLC) were eligible for
randomization to 1 further cycle of either high-dose or
conventional-dose therapy with cyclophosphamide, etopo-
side, and carmustine (BCNU) [13]. Although a clear dose-
response relationship was demonstrated, a dose-survival
relationship was blunted by an 18% toxic death rate on the
autologous bone marrow transplantation arm, which lacked
consolidative thoracic radiotherapy.
The safety of high-dose therapy has improved markedly
over the past 5 to 10 years, particularly with the advent of
peripheral blood progenitor cell (PBPC) support. Thus the
strategies of intensifying induction therapy, dose-intense
chest radiotherapy, and dose-intensive combination therapies
with stem cell support are now much more feasible even in a
more fragile elderly population such as SCLC patients.
We present the long-term outcomes of 36 patients with
ES SCLC or EPSC in partial response (PR) or CR to con-
ventional dose induction chemotherapy who subsequently
received dose-intensive combination alkylating-agent ther-
apy with hematopoietic stem cell support followed by pro-
phylactic cranial radiotherapy. Both high-dose regimens,
CBP and ICE, have known activity against SCLC [14-16].
METHODS
Eligibility
Patients physiologically younger than age 60 years (ie,
patients with a performance status of 0-1 and limited
comorbidity older than age 60 years accepted on a case-by-
case basis) with extensive-stage histologically documented
SCLC or EPSC, in continued response to ﬁrst-line conven-
tional-dose induction chemotherapy, were eligible for
enrollment in this series of sequential studies. After maximal
response from induction chemotherapy (generally approxi-
mately 4 cycles), restaging studies were carried out includ-
ing head, chest, and upper abdominal computerized tomog-
raphy scans; bone scan; bilateral marrow aspirates and
biopsies; and eligibility laboratory tests. Eligibility was spe-
cific to each study, but in general, prior to hematopoietic
stem cell collection, included a Zubrod performance status
of 0 to 1, leukocyte count ≥3000/µL, platelet count
≥100,000/µL, creatinine level ≤1.5 × normal, creatinine
clearance ≥60 mL/min, serum SGOT (aspartate amino-
transferase [AST]) level and bilirubin level ≤1.5 × normal,
forced vital capacity (FVC) and carbon monoxide diffusing
capacity (DLCO) ≥60% of predicted (corrected for hemo-
globin), and left ventricular ejection fraction (LVEF) ≥45%.
Diagnostic pathology or cytology was reviewed by the
Brigham and Women’s Hospital Department of Pathology.
Written informed consent was obtained and the study was
conducted according to the guidelines of the Dana-Farber
Cancer Institute and Beth Israel Deaconess Medical Center
institutional review boards.
Treatment
The treatment schemas and regimens are outlined in
Figure 1.
Induction Therapy. Patients were referred after achieving
PR, near-CR, or CR to combination chemotherapy.
Hematopoietic Stem Cell Collection. Marrow was harvested
under general anesthesia and cryopreserved as previously
described [17]. PBPCs were collected by leukapheresis and cryo-
preserved after mobilization with granulocyte- or granulocyte-
macrophage colony-stimulating factor (GM-CSF) according to
standard methods [17]. Patients were eligible for participation
on several sequential supportive care protocols. Thus, hemato-
poietic support consisted of marrow alone in 8 patients, marrow
augmented by G-CSF– or GM-CSF–mobilized PBPCs in
13 patients, chemotherapy/G-CSF–mobilized PBPCs alone in
13 patients, and cyclophosphamide/G-CSF–mobilized CD34-
selected PBPCs (CellPro Ceprate column; CellPro Inc, Bothell,
WA) in 2 patients.
High-Dose Therapy. The high-dose “intensification”
chemotherapy regimen CBP consisted of cyclophosphamide
(1875 mg/m2 as a 2-hour infusion daily for 3 days), cisplatin
(55 mg/m2 per day by continuous infusion over 72 hours),
and BCNU (60 mg/m2 per dose given as a 1-hour infusion
twice daily for 4 days). The total doses were 5625, 165, and
480 mg/m2, respectively. High-dose intensiﬁcation chemo-
therapy regimen ICE consisted of ifosfamide (4000 mg/m2
per day × 4 days), carboplatin (450 mg/m2 per day × 4 days),
and etoposide (300 mg/m2 per day × 4 days), all given by
continuous intravenous infusion with mesna uroprotection.
The total doses were 16000, 1800, and 1200 mg/m2, respec-
tively [18]. Eight patients received ICE plus etanidazole
[19]. Hematopoietic stem cells were reinfused (day 0) 48 to
72 hours after completion of chemotherapy.
Radiotherapy. Involved-ﬁeld radiotherapy (varied doses)
for patients with oligometastatic disease (3 or fewer metastatic
sites of disease) and prophylactic cranial radiotherapy (30 Gy
in 15 fractions) for complete responders were administered
after complete recovery from the acute side effects of intensi-
ﬁcation chemotherapy. Patients who had received radiother-
apy prior to intensiﬁcation were eligible for protocol.
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Statistical Methods
Standard response criteria were used. CR required total
disappearance of tumor for at least 4 weeks and/or absence
of tumor in surgical biopsy specimens with persistent abnor-
malities. Near-CR was deﬁned as >90% tumor reduction for
at least 4 weeks with persistent radiographic abnormalities
such as residual parenchymal scarring without nodular char-
acteristic, residual pleural or pericardial thickening, or resid-
ual mediastinal adenopathy less than 1.5 cm in greatest
diameter. PR required 50% to 90% reduction for at least
4 weeks of the product of perpendicular diameters of all mea-
surable lesions. Stable disease was deﬁned as <50% reduc-
tion or <25% increase of the same parameters for ≥8 weeks,
and progression of disease (PD) required a ≥25% increase in
lesions or the appearance of any new lesions. Time to failure
was calculated from day 0 of intensiﬁcation (unmaintained
by further systemic therapy) to the documentation of pro-
gression or death from any cause. Survival was calculated
from day 0 of intensiﬁcation to the documentation of death
from any cause. Time to failure and survival were estimated
by the Kaplan-Meier method [20]. Conﬁdence intervals (CI)
were constructed around the Kaplan-Meier estimates using
Greenwood’s variance formula [21]. Univariate comparisons
of these endpoints between patient groups based on pre-
transplantation characteristics, such as induction response,
were made using the log-rank test [22]. Multiple factors
were simultaneously assessed using proportional hazards
regression [23]. However, statistical power is limited
because of small sample sizes. The number of days to granu-
locyte count > 500/µL, to platelet count >20,000/µL, and to
red blood cell (RBC)-transfusion independence were com-
pared between patients treated with and without PBPCs
using a generalized Wilcoxon statistic [21]. This statistic
weights early differences in the time to a particular event
more heavily than late differences. When examining the
time to engraftment, early differences are clinically more
important. This test reduces to the Wilcoxon Rank Sum test
in the absence of censoring.
RESULTS
Patient Characteristics
From July 1987 to May 2000, 29 patients with ES SCLC
and 7 patients with EPSC were enrolled (Table 1). The
patients were selected for PR or better to ﬁrst-line therapy,
lack of significant active comorbid disease, and ability to
obtain ﬁnancial coverage and were referred from all over the
United States. Median age was 49 years (range, 26-61 years);
81% had a performance status of 0 at initiation of high-dose
therapy, and 53% were men. Except for chronic bronchitis
or emphysema, most patients had no active comorbid dis-
ease. Three patients presented with syndromes of inappro-
priate antidiuretic hormone. Of the 7 patients with EPSC,
sites of presentation included respiratory tract in 4 and gas-
trointestinal or gynecologic in 3. Patients had a median of
3 organs/sites of disease involved (range, 1-9 organs/sites).
Figure 1. Treatment schemas and regimens.
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Treatment
A median of 5 cycles of induction chemotherapy was
given (range, 2-10 cycles). Because most patients were
referred after initiation of chemotherapy, varied regimens
were given. Three patients received non–platinum-containing
induction (doxorubicin, vincristine, etoposide, and midcycle
methotrexate [MAVE] or cyclophosphamide, doxorubicin,
and etoposide [CAE]), and 33 received etoposide and either
cisplatin or carboplatin (PE or CbE) regimen; 11 of these
patients received ifosfamide as part of their therapy. Nine
patients achieved CR, 21 near-CR, 5 PR, and 1 PD to
induction therapy (prior to high-dose therapy).
Involved-field radiotherapy to the primary lesion,
hilum, mediastinum, and bilateral supraclavicular areas was
administered in 15 patients. The median doses to the
extended and involved ﬁelds were 41.4 Gy (range, 30-56 Gy)
and 50.2 Gy (range, 43-64.8 Gy), respectively. Radiotherapy
was also given to bony sites in 5 patients, the brain in
4 patients, and the adrenal gland in 1 patient. Prophylactic
cranial irradiation (median dose, 30 Gy; range, 30-36 Gy)
was given to 13 patients in 2-Gy fractions
Toxicity to High-Dose Therapy
Toxicity of therapy (Table 2) has been previously sum-
marized in 2 of the individual studies [18,19]. Etanidazole
proved overly toxic to the liver, kidneys, and peripheral
nerves when combined with high-dose chemotherapy. Four
patients died of toxicity (11%); death was due to renal fail-
ure in 2 patients, Candida infection in the third patient, and
Clostridium difﬁcile infection in the fourth patient.
Median times to granulocyte count ≥500/µL and
platelet count ≥20,000/µL were 11 days (range, 8-33 days)
and 18 days (range, 6-44 days), respectively. Patients who
received PBPCs (n = 28) with or without marrow support
recovered granulocytes (median of 10 days versus 29 days to
granulocyte count ≥500/µL; P = .006) and platelets (median
of 16 days versus 29 days to platelet count ≥20,000/µL; P =
.026) more quickly than those who received marrow alone
(n = 8). Platelet reconstitution was faster for patients who
received chemotherapy/G-CSF–mobilized PBPCs than for
those who received G-CSF– or GM-CSF–mobilized PBPCs
(median of 10 days versus 20 days; P = .01). Patients under-
went transfusion with a median of 10 units (range, 2-33 units)
of packed RBCs and a median of 70 units (range, 0-292 units)
of platelets. Two patients had severe alloimmunization
resulting in refractory thrombocytopenia associated with
bleeding. Acutely, all patients required antibiotics for sup-
port of fever during neutropenia.
Nonhematologic toxicities of the CBP and ICE regi-
mens are compared in Table 2. Interstitial pneumonitis and
grade 3 and 4 ototoxicity were more commonly seen follow-
ing treatment with CBP; mucositis and elevations in AST,
bilirubin, and creatinine levels were more commonly seen
following treatment with ICE. These observations are con-
sistent with the phase I/II literature concerning these
regimens. Interstitial pneumonitis related to BCNU is
reversible in large part with prednisone 1 mg/kg followed by
a gradual taper over 6 to 8 weeks. These patients received
Table 2. Nonhematologic Toxicity of CBP and ICE Regimens
CBP ICE P*
Patients 13 23
Death within 90 days† 1 3 NS
Line infections 4 6 NS
Reversible congestive heart failure 1 1 NS
Interstitial pneumonitis requiring steroids 4 0 .04
Creatinine median, mg/dL 1.3 1.5 NS
Creatinine mean, mg/dL 1.59 3.26 .027
Ototoxicity (grade 3-4) 9 7 .035
AST (grade 3-4) 0 8 .002
Bilirubin (grade 3-4) 2 8 .17
Mucositis (grade 3-4) 1 10 .008
*Two-tailed t test.
†Candida sepsis, renal failure (n = 2), Clostridium difﬁcile.
Table 1. Characteristics of 36 Patients with Extensive-Stage SCLC or
Extrapulmonary Small Cell Carcinoma*
Characteristic No. of Patients (Range)%
All patients 36
ES SCLC 29
EPSC† 7
Median age 49 (26-61)
Male/female 19/17 53/47
Median pack-years smoking 39 (0-140)
SCLC 47.5 (20-140)
EPSC 0 (0-20)
Prognostic factors prior to induction 
therapy
Performance status 0 at diagnosis 15 42
>5% weight loss within 6 months 8 22 
prior to diagnosis
Paraneoplastic syndrome 3 8
Abnormal LDH >600 (n = 24) 15 63
CEA ≥5 prior to therapy (n = 15) 8 53
TNM stage (SCLC only)
T1N0M1 1 3
T1-3N2M1 12 41
Tx-2N3M1 3 10
T3N3M1 5 17
T4N2-3M1 8 28
Sites of metastatic disease
No. of organs involved 3 (2-9)
Visceral (BM, Br, L, Sp, GI, A) 23 64
Median no. of induction cycles 5 (2-10)
Months from diagnosis to high-dose 6 (2-10) 
therapy
Best response to induction
Complete response 9 25
Near-complete response (VGPR, PR)† 21 58
Partial response 5 14
Progressive disease 1 3
*LDH indicates lactate dehydrogenase; CEA, carcinoembryonic
antigen; TNM, (primary) tumor, (regional lymph) node, (remote)
metastases (classiﬁcation, staging); Br, brain; L, liver; Sp, spleen; GI,
gastrointestinal tract; A, adrenal; VGPR, very good partial response. 
†EPSC primary sites (residual disease at induction): esophageal
(liver, nodes), parotid (cervical nodes), sinus (inoperable ethmoid/
maxillary sinus), tongue (primary, cervical and supraclavicular nodes),
colon (liver), gynecologic (liver, peritoneum, abdominal wall, spleen),
pelvis (pelvic organs, nodes).
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prophylactic acyclovir and trimethoprim sulfazoxasole.
Typhlitis and pneumonia occurred during the transplanta-
tion course in 2 and 3 patients, respectively. One patient
developed transient hemolytic uremic syndrome 7 months
post-CBP treatment.
Response to High-Dose Chemotherapy
Of 36 patients, 19 (53%) were not evaluable for response
to high-dose chemotherapy (6 were in CR, 9 were in near-
CR, and 4 died of treatment-related toxicity). Of 17 patients
evaluable for response, the overall PR-to–CR/near-CR con-
version rate was 53%. Two patients progressed with carcino-
matous meningitis during the high-dose cycle on day +5.
Time to Failure and Relapse
The median times to failure from initiation of induction
chemotherapy and after high-dose therapy for all patients
were 12 and 5 months, respectively (Figure 2). All 6 patients
who achieved ≤PR prior to high-dose therapy relapsed in a
median of 3 months (range, 0.2-12 months). For all patients
(n = 36), the 1-, 2-, and 5-year relapse-free survival was
24% (95% CI, 14%-44%), 12% (95% CI, 5%-31%), and
9% (95% CI, 3%-27%). The median event-free survival
(EFS) for EPSC was 6 months (95% CI, 4-10 months).
The median time from relapse to death was 3 months (range,
0-65 months). Sites of relapse were predominantly in unirra-
diated prior sites of disease. Five patients (2 SCLC, 3 EPSC)
remained in continuous remission for a median of 55 months
(range, 1-96 months). Four patients were progression free
with follow-up more than 24 months following transplanta-
tion (2 SCLC, 2 EPSC). Three patients remained progres-
sion free long-term: 1 EPSC patient (parotid primary) had
only local nodal metastases, and the other (colon primary)
had diffuse liver disease; 1 SCLC patient had T3N3 plus
Figure 2. Overall survival (OS): time from initiation of high-dose chemotherapy to death from any cause; and event-free survival: time from initia-
tion of high-dose chemotherapy to ﬁrst failure (progression of disease or death from other causes) determined by Kaplan-Meier method. A, EFS and
OS for all patients (n = 36), from day 1 of transplantation. B, EFS and OS of ES SCLC patients (n = 29), from day 1 of transplantation; EFS and OS
for EPSC patients (n = 7), from day 1 of transplantation. (/) indicates follow-up time for patients.
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contralateral lung metastasis. One SCLC patient with TxN3
and 3 to 4 foci of bone disease relapsed with SCLC at
26 months and lived a total of 91 months.
Survival
The median survival times from initiation of induction
chemotherapy and after high-dose therapy for all patients
were 23 and 18 months, respectively (Figure 2). Thirteen
patients remained alive with a median follow-up of 7 months
(range, 1-96 months) after high-dose therapy. After intensi-
ﬁcation the probability of survival at 1 year was 61% (95%
CI, 45%-81%), at 2 years was 28% (95% CI, 15%-52%),
and at 5 years was 19% (95% CI, 8%-43%).
Cox Regression Analysis 
The following factors were analyzed for survival and
progression-free survival after high-dose chemotherapy: age
(<50 versus >50), sex, EPSC versus SCLC, number of
organs involved (1-2 versus 3 versus >3), number of cycles of
induction (≤4 versus >4), months of induction, the degree of
response to induction chemotherapy (CR/near-CR versus
≤PR), regimen (CBP versus ICE, for SCLC only), thoracic
radiation therapy given (yes versus no), performance status
at diagnosis (0 versus 1-4), and weight loss >5% at diagnosis
(yes versus no) (Table 3). Factors associated with more
favorable rates of EFS were the use of a more aggressive
induction regimen (ICE; P = .03) and the EPSC histology
(P = .02). Factors associated with more favorable overall sur-
vival included these 2 factors (P = .009 and .006, respec-
tively) and also the use of short induction (≤4 cycles, P =
.009) and younger age (<50 years, P = .05).
DISCUSSION
Higher rates of overall survival and CR are achieved by
high-dose therapy than by conventional-dose therapy for a
variety of hematologic and epithelial malignancies. In some
malignancies, such as breast cancer, a dose-survival advan-
tage of about 10% absolute has been suggested by promis-
ing results in phase II trials, although the phase III studies
large enough to detect this degree of beneﬁt are either not
yet mature enough or have not yet been completed. In other
malignancies, such as multiple myeloma and certain subsets
of lymphoma, high-dose therapy with autologous hemato-
poietic support does provide a modest survival advantage in
randomized trials. A small randomized trial in SCLC com-
paring conventional therapy to high-dose intensification
proved the principle but resulted in an unacceptable 18%
mortality [13]. A number of other phase I/II high-dose trials
in SCLC have produced enhanced CR rates without obvi-
ous long-term survival benefit, particularly given patient
selection biases and the high morbidity of treatment [24].
We have recently published our long-term follow-up results
for patients with limited-stage SCLC responding to first-
line therapy. Those near or in CR had a 53% 5-year EFS
[25]. Although these outcomes should encourage further
evaluation of this approach for the treatment of limited-
stage SCLC, selection bias may have contributed to the
favorable results; randomized studies remain a priority but
are proving difﬁcult to mount or complete.
In this study, we were able to deliver high-dose com-
bined alkylating-agent therapy relatively safely, consistent
with the substantial decline in the morbidity and mortal-
ity from high-dose chemotherapy with the development
of PBPCs and hematopoietic cytokines. As a result, over the
past 5 years, the upper age range of transplantation candidates
has increased from 50 years to 65 years. It is noteworthy in
the present study that, due in part to their nonsmoking sta-
tus, patients with EPSC experienced lower morbidity and
mortality and higher rates of survival than did ES SCLC
patients (P = .009).
For a selected group of ES SCLC patients, we report
12% and 28% 2-year EFS and overall survival rates, respec-
tively. Although the 2-year survival rate compares favorably
with that for conventional-dose therapies in treatment of ES
SCLC, selection biases favoring our patients, including
younger age, a relative lack of comorbid disease, the insistence
that they cease smoking, and tolerance to and excellent
response to induction therapy, are probable contributors for
this positive result. Further investigation using high-
dose therapy in ES SCLC should focus on multicycle non–
cross-resistant high-dose approaches rather than a single
cycle of “late intensiﬁcation” in the attempt to improve out-
come. On the other hand, of the 7 patients with EPSC,
4 remained alive and 3 were relapse free at the time of this
report. Given the expected poor prognosis for these patients,
further phase II study is warranted in this subgroup.
Based on our observations, several other strategies could
be explored to try to improve results: shorter initial therapy
and earlier intensification, double transplantation, support
with purged/selected stem cells, and the development of
non–cross-resistant immunologic therapy targeting minimal
disease. Earlier intensification of induction may improve
overall disease-free and overall survival rates [26]. Multicy-
cle dose-intensive combination therapies supported by
cytokines and PBPCs represent logical promising treatment
concepts [16,27,28]. Whether involved-ﬁeld radiotherapy is
beneﬁcial in oligometastatic disease is unclear.
Stem cell contamination with tumor cells surviving
induction therapy may be a source of relapse. As has been
reviewed elsewhere, bone marrow is frequently involved in
SCLC [29-33]. Early intensiﬁcation using stem cell support
Table 3. Favorable Prognostic Factors: Cox Regression Analysis
Factor Progression-Free Survival Overall Survival
Histology EPSC versus SCLC P = .02 P = .006
Induction regimen ICE versus no ICE P = .03 P = .009
Induction duration ≤4 versus >4 cycles P = .10 P = .009
Age ≤50 years versus >50 years P = .13 P = .05
Response to induction CR/near-CR versus PR P = .26 P = .09
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derived from untreated or post–ﬁrst-cycle therapy may have a
high rate of tumor contamination [34]. Even after achieving
CR to chemotherapy, a high rate of residual contamination is
observed [35-38]. Thus, stem cell selection may further
enhance outcome. More importantly, these residual cells may
represent a distinct subpopulation of tumor cells with identi-
ﬁable biological features that confer not only drug-resistance
phenotypes but perhaps also tumor stem cell properties.
High-dose therapy for ES SCLC should only be per-
formed in the context of a clinical investigation and should
focus on highly selected individuals with oligometastatic dis-
ease in excellent primary response or at the time of initial
presentation. Further phase II experience in the consolida-
tion of chemoresponsive disease for EPSC is warranted.
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